Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- ‘Having women at the top’ drives structural change, advances gender equity in GI (Healio)
- Virgo Launches EndoML: A Revolutionary AI Platform Powered by the EndoDINO Foundation Model (PR Newswire)
- Improved physician ADR from a baseline of less than 26% linked to lower CRC risk (Healio)
- AGA Clinical Practice Update on Endoscopic Enteral Access: Commentary (Gastro Journal)
- Top Gastrointestinal Cancer Research of 2024 (Gastroenterology Advisor)
- How Physicians Can Prepare for a Private Equity Exit with Rob Greer, Founder of SovDoc (State of MedTech)
- World’s largest proteins study ‘invaluable’ for understanding disease – experts (Independent)
- Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes (Fierce Healthcare)